Edesa biotech, inc. (SBOT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Aug'14Jun'14Mar'14Dec'13
Net loss

-1,489

-1,094

-

-

-528

-364

-1,129

-1,156

-1,352

-1,400

-1,220

-1,220

-1,103

-1,485

-1,341

-1,194

-861

-1,629

-1,537

463

-426

-1,343

-4,836

3,408

-1,433

-5,577

Adjustments for:
Depreciation

2

2

2

1

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Straight-line operating lease expense

19

19

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

46

49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

44

45

45

42

37

36

32

40

41

40

37

37

41

47

31

Share-based compensation

380

8

10

11

13

11

86

-26

73

20

23

27

28

36

49

42

42

124

22

45

112

86

185

156

145

468

Foreign exchange (gain) loss

-

-

-

-

-

-

12

-13

-16

-17

140

64

35

-77

-32

-8

226

-109

-262

77

-307

-161

-169

146

-182

-16

(Gain) loss in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-211

-324

1,254

1,061

139

-3,367

4,528

185

-3,880

Transfer equipment to research and development

-

-

-

-

-

-

0

0

1

10

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in equity investment in joint venture

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in working capital items:
Accounts and other receivable

-18

-108

-126

97

19

-3

34

-55

51

9

-10

-54

52

-72

76

-1

-25

-121

44

96

-18

-8

42

-75

-87

0

Prepaid expenses and other assets

98

-125

45

251

14

-6

19

-142

50

35

-197

-55

8

9

235

-73

-32

67

-92

110

63

-36

-11

76

31

-2

Inventory

-

-

-

-

-

-105

-13

32

86

50

-72

-169

-19

80

-319

25

15

-29

362

59

0

99

0

0

158

-158

Accounts payable and accrued liabilities

-99

175

-544

-1,488

150

-38

-76

-19

15

253

-104

-8

-168

-21

-42

222

-280

67

288

-43

-135

-33

330

-30

-126

-67

Operating lease liabilities

19

19

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-173

0

173

-86

0

15

0

0

0

Net cash used in operating activities

-1,170

-789

-1,326

-3,120

-398

-382

-2,783

700

-1,388

-1,144

-1,117

-941

-1,276

-1,365

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Proceeds on sales of property and equipment

20

22

18

18

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,066

-1,072

-1,174

-

-915

-1,295

-1,285

-606

-1,100

-1,473

-1,086

Purchase of property and equipment

-

-

5

-340

342

-341

341

-164

171

34

102

73

42

84

107

31

88

175

71

145

18

38

0

27

41

209

Purchase of short-term investments

0

499

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

3,114

5,463

501

4

1,996

1,003

2,000

4

5,989

3,999

2,004

1

0

5

5

1

-

-

-

0

Proceeds on sales and maturities of short-term investments

-

-

-

-

-

-

2,500

500

1,000

1,000

4,000

1,000

2,000

0

-

-

-

-

-8

-5

-18

442

0

0

0

0

Net cash provided by (used in) investing activities

519

-477

12

6,406

-1

0

-5,420

-334

327

961

1,900

-76

-43

-89

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Payments for issuance costs

352

116

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-98

2,929

-176

-

-156

-42

402

-5,467

-27

-41

-209

Proceeds from common shares subscribed

-

45

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,368

78

0

0

28

1,345

0

405

2,557

Net cash provided by financing activities

3,846

45

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-33

18

-18

34

75

19

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,368

-

0

0

28

7,824

0

405

2,557

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

12

-13

-16

-17

139

64

35

-77

-26

-9

217

-85

-273

82

-285

-153

-152

145

-191

-14

Net change in cash and cash equivalents

3,162

-1,203

-1,332

3,320

-324

-363

918

14

-1,076

-201

923

-953

-1,284

-1,531

2,629

-1,174

2,074

-67

-1,191

-989

-1,623

-1,007

1,599

-982

-1,300

1,247

Supplemental disclosure of non-cash financing activities
Cash paid during the period for taxes

-

-

-

-

-

-

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-